Contract Pharma | Pharma Matters Q&A interview with our CEO, Jarlath Keating
A conversation with Jarlath Keating, CEO of Phosphorex, on the future of LNPs in pharmaceutical innovation.
In recent years, lipid nanoparticles (LNPs) have emerged as a groundbreaking technology in the pharmaceutical world, revolutionizing the delivery of complex therapeutic molecules like RNA and DNA.
Glioblastoma (GBM) is a malignant brain tumor that remains among the most formidable cancers.Despite a well-established standard of care of maximal surgical resection followed by radiotherapy plus concomitant temozolomide (TMZ), median survival remains approximately 15 months.